[Feasibility and reliability of a transtelephonic 12 leads ECG].

Feasibility and reliability of a 12 lead electrocardiogram (ECG), recorded by the patient himself and transmitted via telephone are mandatory for prehospital diagnosis of myocardial ischemia in patients with coronary heart disease. In this study, a 12-lead ECG recorded by patients and transmitted to the cardiology call center via telephone (Tele-ECG; model CG-7100; Card Guard) was compared with the conventional 12-lead ECG from the same patient recorded at the same time in 128 cases. The Tele-ECGs received by the call center were compared with conventional ECG by two cardiologists and one internist independently and blindly.

Embolization of a rubber disc from a hemostasis valve: technical note.

After coronary angioplasty, a patient experienced a sudden onset of claudication at the side of the vascular entry. Angiography demonstrated an isolated high-grade stenosis at the bifurcation of the distal popliteal artery. Thrombolysis and angioplasty were unsuccessful.

Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).

The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomized multicenter trial in 246 patients with acute myocardial infarction of less than 6 h duration. Both 70 mg of single chain rt-PA with an initial bolus of 10 mg and 3 million units of urokinase with an initial bolus of 1.5 million units were given intravenously over 90 min.

[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].

The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomised multicenter trial in up to now 125 patients with acute myocardial infarction of less than six hours duration. Both, 70 mg of single-chain rt-PA with an initial bolus of 10 mg, and 3 million U of urokinase with an initial bolus of 1,5 million U were given intravenously over 90 minutes. The first angiogram at the end of the infusion revealed a patent infarct-related artery (TIMI grade 2 or 3) in 68% of 62 patients with rt-PA vs.

Inhibition of thrombocyte aggregation by oral motapizone and other drugs.

Ten healthy subjects took single oral doses of placebo, 8.8 +/- 1.8 mg motapizone, 40 +/- 13 mg captopril, 25 mg dihydralazine, 20 mg nifedipine and 4.